Trans-Pacific Partnership Agreement: Harmful provisions for access to medicinesPacific Partnership Agreement • May 16th, 2014
The Trans-Pacific Partnership (TPP) is a proposed free trade agreement between 12 countries in the Asia-Pacific including the United States. According to leaked texts, the U.S. seeks to expand pharmaceutical monopolies at the expense of consumers’ health despite significant opposition from negotiation partners. In 2001, all World Trade Organization (WTO) members—including the U.S.—agreed that patent rights should not block access to affordable medicines and that IP rules should not interfere with countries’ public health agenda. In the TPP, however, the United States Trade Representative (USTR) is proposing measures that would limit generic competition, raise drug prices for consumers, and constrain future innovation in the Asia-Pacific. Almost all TPP countries oppose these proposals and some countries have heroically championed pro-competition and pro-health alternative measures. This chart provides an explanation of harmful provisions for access to medicines and their potential impa
Trans-Pacific Partnership Agreement (CPTPP) Amendment Act 2018Pacific Partnership Agreement • December 7th, 2020
TRANS-PACIFIC PARTNERSHIP AGREEMENT – INTELLECTUAL PROPERTY CHAPTERPacific Partnership Agreement • January 8th, 2018
The Trans-Pacific Partnership Agreement is a free trade agreement between Australia, Brunei, Chile, Canada, the United States, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. After 7 years of negotiations, which began in February 2008, an agreement was reached on October 5, 2015, and the text was published in English on November 5, 2015. Among other matters, the TPP seeks to establish a common framework for intellectual property, strengthen labor law and environmental law standards, and establish an arbitration mechanism to solve dis- putes between States and investors.
THE TRANS-‐PACIFIC PARTNERSHIP AGREEMENT MEANS MORE, FASTER, EASIER INTERNATIONAL TRADEPacific Partnership Agreement • January 11th, 2011
At a time when international trade has slowed down significantly, the Trans-‐Pacific Partnership represents an unparalleled opportunity to take the cost, time and complexity out of international trade by setting high global standards for the 21st century economy.
Trans-Pacific Partnership Agreement (TPP): Alcoholic Beverages and Health Information/Warning LabelsPacific Partnership Agreement • November 28th, 2015
Trans Pacific Partnership Agreement and Access to MedicinesPacific Partnership Agreement • February 19th, 2012
• Trans-Pacific Partnership AgreementPacific Partnership Agreement • August 19th, 2013
• no logos, brand imagery, symbols, other images, colours or promotional text on tobacco products or tobacco product packaging
Trans-Pacific Partnership Agreement and the public healthPacific Partnership Agreement • July 13th, 2015
The Trans-Pacific Trade Agreement (TPPA) negotiations have been conducted in secrecy over the past four years. In New Zealand, the government has not released any official details of these negotiations and all the information we have about TPPA is derived from leaks. This makes any analysis of the risks and benefits of TPPA difficult to carry out. However, the consistency of the leaked material indicates that the TPPA appears to have major implications for the New Zealand health system, potentially adversely affecting public health initiatives, the control of alcohol and obesity problems, and reducing the availability of some drugs. This article describes the basis for these concerns, and aims to show that the TPPA could interfere with our ability to organise our health systems, now and in the future, for the best interests of all the people of New Zealand.
